7,400 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by OPTIMAS CAPITAL Ltd

OPTIMAS CAPITAL Ltd purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, HoldingsChannel.com reports. The firm purchased 7,400 shares of the medical research company’s stock, valued at approximately $3,000,000. Thermo Fisher Scientific comprises 3.2% of OPTIMAS CAPITAL Ltd’s holdings, making the stock its 12th biggest holding.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Thermo Fisher Scientific by 0.9% in the second quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock valued at $13,700,154,000 after buying an additional 309,207 shares during the period. Franklin Resources Inc. raised its stake in shares of Thermo Fisher Scientific by 11.3% in the 2nd quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock valued at $1,985,759,000 after acquiring an additional 498,238 shares during the period. Amundi boosted its position in Thermo Fisher Scientific by 5.9% during the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock worth $1,426,316,000 after purchasing an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. raised its position in Thermo Fisher Scientific by 2.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock valued at $1,216,612,000 after purchasing an additional 74,971 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after purchasing an additional 329,974 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 4,638 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $594.42, for a total transaction of $2,756,919.96. Following the completion of the transaction, the chief operating officer directly owned 23,480 shares of the company’s stock, valued at $13,956,981.60. The trade was a 16.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 7,250 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $566.10, for a total value of $4,104,225.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $64,400,668.20. This trade represents a 5.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 52,570 shares of company stock worth $30,382,352. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 0.7%

TMO stock opened at $593.41 on Thursday. The firm has a fifty day moving average price of $544.05 and a two-hundred day moving average price of $477.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The firm has a market cap of $222.95 billion, a price-to-earnings ratio of 34.28, a PEG ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the prior year, the firm earned $5.28 EPS. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its board has initiated a stock repurchase plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.94%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TMO. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Citigroup upped their price objective on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. JPMorgan Chase & Co. lifted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company raised their price target on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Nineteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.